|
OMIM |
Link |
Information gain |
01 |
|
IDDM
|
[NCBI]
|
0.0143996
|
|
|
RA
|
[NCBI]
|
0.0120291
|
|
|
sjogren syndrome
|
[NCBI]
|
0.0023866
|
|
|
panbronchiolitis, diffuse
|
[NCBI]
|
0.00176246
|
|
|
narcolepsy 2
|
[NCBI]
|
0.00165623
|
|
|
myositis
|
[NCBI]
|
0.00165623
|
|
|
azoospermia, nonobstructive
|
[NCBI]
|
0.00165623
|
|
|
CF
|
[NCBI]
|
0.00134115
|
|
|
alopecia areata 1
|
[NCBI]
|
0.00132529
|
|
|
myasthenia gravis with thymus hyperplasia
|
[NCBI]
|
0.000944774
|
|
|
hypoadrenocorticism, familial
|
[NCBI]
|
0.000944774
|
|
|
IDDM15
|
[NCBI]
|
0.000944774
|
|
|
IDDM3
|
[NCBI]
|
0.000944774
|
|
|
nasopharyngeal carcinoma 1
|
[NCBI]
|
0.000821185
|
|
|
temporal arteritis
|
[NCBI]
|
0.000750675
|
|
|
bare lymphocyte syndrome, type ii
|
[NCBI]
|
0.000744534
|
|
|
HLP
|
[NCBI]
|
0.000730485
|
|
|
HLA-DRA
|
[NCBI]
|
0.000685062
|
|
|
hla-d histocompatibility type
|
[NCBI]
|
0.00068022
|
|
|
HLA-DRB1
|
[NCBI]
|
0.000597085
|
|
|
IDDM4
|
[NCBI]
|
0.0005512
|
|
|
MS
|
[NCBI]
|
0.000519088
|
|
|
IGES
|
[NCBI]
|
0.000508573
|
|
|
APS2
|
[NCBI]
|
0.000508573
|
|
|
TNF
|
[NCBI]
|
0.000496628
|
|
|
CD
|
[NCBI]
|
0.000374261
|
|
|
hashimoto thyroiditis
|
[NCBI]
|
0.000334942
|
|
|
apnea, obstructive sleep
|
[NCBI]
|
0.000323693
|
|
|
HLA-DQB1
|
[NCBI]
|
0.000322162
|
|
|
AD
|
[NCBI]
|
0.000316452
|
|
|
MBP
|
[NCBI]
|
0.000283914
|
|
|
IGAD1
|
[NCBI]
|
0.000232352
|
|
|
PEE1
|
[NCBI]
|
0.000232352
|
|
|
IGAN1
|
[NCBI]
|
0.000206603
|
|
|
diabetes mellitus, insulin-dependent, 2
|
[NCBI]
|
0.000206603
|
|
|
HLA-DQA1
|
[NCBI]
|
0.000205533
|
|
|
pars planitis
|
[NCBI]
|
0.000189051
|
|
|
graves disease
|
[NCBI]
|
0.00017009
|
|
|
pemphigus vulgaris, familial
|
[NCBI]
|
0.000155238
|
|
|
CJD
|
[NCBI]
|
0.000134903
|
|
|
NRCLP1
|
[NCBI]
|
0.000125193
|
|
|
mast cell disease
|
[NCBI]
|
0.000113455
|
|
|
HLA-A
|
[NCBI]
|
0.000105629
|
|
|
panencephalitis, subacute sclerosing
|
[NCBI]
|
0.000100763
|
|
|
IS
|
[NCBI]
|
9.54293e-05
|
|
|
streptococcus, group a, severity of infection by
|
[NCBI]
|
9.45143e-05
|
|
|
pancreatitis, sclerosing cholangitis, and sicca complex
|
[NCBI]
|
9.45143e-05
|
|
|
MICA
|
[NCBI]
|
9.05971e-05
|
|
|
HLA-MT
|
[NCBI]
|
8.96414e-05
|
|
|
TINU
|
[NCBI]
|
8.87093e-05
|
|
|
HLA-DPA1
|
[NCBI]
|
8.60476e-05
|
|
|
VEGF
|
[NCBI]
|
8.08928e-05
|
|
|
RP
|
[NCBI]
|
7.98354e-05
|
|
|
sarcoidosis
|
[NCBI]
|
7.79185e-05
|
|
|
takayasu arteritis
|
[NCBI]
|
7.79185e-05
|
|
|
HLA-DPB1
|
[NCBI]
|
7.61166e-05
|
|
|
TPO
|
[NCBI]
|
7.19754e-05
|
|
|
MG
|
[NCBI]
|
7.03884e-05
|
|
|
autoimmune disease
|
[NCBI]
|
6.94665e-05
|
|
|
CVID
|
[NCBI]
|
6.61784e-05
|
|
|
RFX5
|
[NCBI]
|
6.56275e-05
|
|
|
t-cell subgroups, non-hla-linked
|
[NCBI]
|
6.32861e-05
|
|
|
epstein-barr virus, susceptibility to chronic infection by
|
[NCBI]
|
6.32861e-05
|
|
|
blepharospasm, benign essential
|
[NCBI]
|
6.32861e-05
|
|
|
OCP
|
[NCBI]
|
6.12015e-05
|
|
|
MHC2TA
|
[NCBI]
|
6.04541e-05
|
|
|
FMF
|
[NCBI]
|
5.91722e-05
|
|
|
HLA-DRB5
|
[NCBI]
|
5.75576e-05
|
|
|
IL16
|
[NCBI]
|
5.74526e-05
|
|
|
FTD
|
[NCBI]
|
5.40108e-05
|
|
|
IK
|
[NCBI]
|
5.29456e-05
|
|
|
VRNI
|
[NCBI]
|
5.20432e-05
|
|
|
glaucoma, normal tension, susceptibility to
|
[NCBI]
|
5.1725e-05
|
|
|
hepatitis b vaccine, response to
|
[NCBI]
|
5.1725e-05
|
|
|
TG
|
[NCBI]
|
5.05483e-05
|
|
|
NFKBIL1
|
[NCBI]
|
4.97825e-05
|
|
|
thrombocytopenic purpura, autoimmune
|
[NCBI]
|
4.75126e-05
|
|
|
RFXANK
|
[NCBI]
|
4.73608e-05
|
|
|
SLE
|
[NCBI]
|
4.61558e-05
|
|
|
ALD
|
[NCBI]
|
4.56657e-05
|
|
|
EGF
|
[NCBI]
|
4.49284e-05
|
|
|
PDB1
|
[NCBI]
|
4.43445e-05
|
|
|
bare lymphocyte syndrome, type i
|
[NCBI]
|
4.43445e-05
|
|
|
NGFB
|
[NCBI]
|
4.29405e-05
|
|
|
lymphoma, non-hodgkin, familial
|
[NCBI]
|
4.25516e-05
|
|
|
CD74
|
[NCBI]
|
4.23115e-05
|
|
|
immunodeficiency with hyper-igm, type 2
|
[NCBI]
|
3.89494e-05
|
|
|
XBP1
|
[NCBI]
|
3.79916e-05
|
|
|
DSG3
|
[NCBI]
|
3.64547e-05
|
|
|
TAP1
|
[NCBI]
|
3.56259e-05
|
|
|
periodontitis, aggressive, 1
|
[NCBI]
|
3.47238e-05
|
|
|
nasopharyngeal carcinoma
|
[NCBI]
|
3.47238e-05
|
|
|
immunodeficiency with hyper-igm, type 3
|
[NCBI]
|
3.47238e-05
|
|
|
CREBL1
|
[NCBI]
|
3.38812e-05
|
|
|
PTPN22
|
[NCBI]
|
3.31294e-05
|
|
|
NFX1
|
[NCBI]
|
2.64673e-05
|
|
|
BAT2
|
[NCBI]
|
2.64673e-05
|
|
|
HEXIM1
|
[NCBI]
|
2.64673e-05
|
|
|
ICAM1
|
[NCBI]
|
2.61598e-05
|
|
|
hepatitis b virus, susceptibility to
|
[NCBI]
|
2.5874e-05
|
|
|
severe cutaneous adverse reaction, susceptibility to
|
[NCBI]
|
2.5874e-05
|
|
|
antiphospholipid syndrome
|
[NCBI]
|
2.36996e-05
|
|
|
STEAP
|
[NCBI]
|
2.36749e-05
|
|
|
IGLP1
|
[NCBI]
|
2.36749e-05
|
|
|
HLA-DNA
|
[NCBI]
|
2.36749e-05
|
|
|
FCRL3
|
[NCBI]
|
2.36749e-05
|
|
|
C4B
|
[NCBI]
|
2.34767e-05
|
|
|
C4A
|
[NCBI]
|
2.32654e-05
|
|
|
PRAME
|
[NCBI]
|
2.18648e-05
|
|
|
LILRB3
|
[NCBI]
|
2.18648e-05
|
|
|
LILRA3
|
[NCBI]
|
2.18648e-05
|
|
|
PSMB8
|
[NCBI]
|
2.18648e-05
|
|
|
THC2
|
[NCBI]
|
2.17799e-05
|
|
|
LILRB2
|
[NCBI]
|
2.05214e-05
|
|
|
BTNL2
|
[NCBI]
|
2.05214e-05
|
|
|
INS
|
[NCBI]
|
2.05099e-05
|
|
|
BCR
|
[NCBI]
|
1.99314e-05
|
|
|
CRH
|
[NCBI]
|
1.97842e-05
|
|
|
IL2
|
[NCBI]
|
1.94973e-05
|
|
|
IGLL1
|
[NCBI]
|
1.94527e-05
|
|
|
HLA-DMA
|
[NCBI]
|
1.94527e-05
|
|
|
HRK
|
[NCBI]
|
1.85656e-05
|
|
|
DPYSL2
|
[NCBI]
|
1.85656e-05
|
|
|
omenn syndrome
|
[NCBI]
|
1.85299e-05
|
|
|
VIP
|
[NCBI]
|
1.8179e-05
|
|
|
BAT1
|
[NCBI]
|
1.78075e-05
|
|
|
LILRB1
|
[NCBI]
|
1.78075e-05
|
|
|
TICAM2
|
[NCBI]
|
1.7146e-05
|
|
|
PSMB9
|
[NCBI]
|
1.7146e-05
|
|
|
RFXAP
|
[NCBI]
|
1.7146e-05
|
|
|
TRAF1
|
[NCBI]
|
1.65593e-05
|
|
|
MPO
|
[NCBI]
|
1.63651e-05
|
|
|
AIRE
|
[NCBI]
|
1.62102e-05
|
|
|
CD3E
|
[NCBI]
|
1.60325e-05
|
|
|
FTLDU
|
[NCBI]
|
1.5872e-05
|
|
|
CTSS
|
[NCBI]
|
1.55546e-05
|
|
|
MATN1
|
[NCBI]
|
1.55546e-05
|
|
|
BDNF
|
[NCBI]
|
1.54398e-05
|
|
|
IL4
|
[NCBI]
|
1.52751e-05
|
|
|
leber optic atrophy
|
[NCBI]
|
1.52479e-05
|
|
|
NSEP1
|
[NCBI]
|
1.51174e-05
|
|
|
SPN
|
[NCBI]
|
1.51174e-05
|
|
|
KLK3
|
[NCBI]
|
1.50647e-05
|
|
|
DRD5
|
[NCBI]
|
1.39937e-05
|
|
|
C5
|
[NCBI]
|
1.36684e-05
|
|
|
CCL19
|
[NCBI]
|
1.36684e-05
|
|
|
PPH1
|
[NCBI]
|
1.36523e-05
|
|
|
HLF
|
[NCBI]
|
1.33628e-05
|
|
|
JK
|
[NCBI]
|
1.33628e-05
|
|
|
FCGR3A
|
[NCBI]
|
1.33628e-05
|
|
|
CD40
|
[NCBI]
|
1.30747e-05
|
|
|
PDB
|
[NCBI]
|
1.26739e-05
|
|
|
hodgkin lymphoma
|
[NCBI]
|
1.26739e-05
|
|
|
CTSD
|
[NCBI]
|
1.22985e-05
|
|
|
G6PC2
|
[NCBI]
|
1.20646e-05
|
|
|
POF1
|
[NCBI]
|
1.17702e-05
|
|
|
ALPS
|
[NCBI]
|
1.17096e-05
|
|
|
AGER
|
[NCBI]
|
1.08351e-05
|
|
|
CD44
|
[NCBI]
|
1.06808e-05
|
|
|
IFNGR1
|
[NCBI]
|
1.06808e-05
|
|
|
PSORS1
|
[NCBI]
|
1.06783e-05
|
|
|
IL1A
|
[NCBI]
|
1.01909e-05
|
|
|
HFE
|
[NCBI]
|
1.01446e-05
|
|
|
FTL
|
[NCBI]
|
1.00382e-05
|
|
|
adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency
|
[NCBI]
|
9.68802e-06
|
|
|
LIP
|
[NCBI]
|
9.43366e-06
|
|
|
LPL
|
[NCBI]
|
9.3979e-06
|
|
|
PRL
|
[NCBI]
|
9.06002e-06
|
|
|
TNFSF6
|
[NCBI]
|
8.96822e-06
|
|
|
complement component 2 deficiency
|
[NCBI]
|
8.84996e-06
|
|
|
TNFRSF1B
|
[NCBI]
|
8.84996e-06
|
|
|
GRN
|
[NCBI]
|
8.84996e-06
|
|
|
hepatitis c virus, susceptibility to
|
[NCBI]
|
8.76043e-06
|
|
|
CHAT
|
[NCBI]
|
8.51571e-06
|
|
|
DSG1
|
[NCBI]
|
8.51341e-06
|
|
|
IFNG
|
[NCBI]
|
8.00293e-06
|
|
|
DCT
|
[NCBI]
|
7.72261e-06
|
|
|
F13A1
|
[NCBI]
|
7.21082e-06
|
|
|
CFB
|
[NCBI]
|
7.21082e-06
|
|
|
NFKB1
|
[NCBI]
|
7.05292e-06
|
|
|
A2M
|
[NCBI]
|
6.90069e-06
|
|
|
PDCD8
|
[NCBI]
|
6.86256e-06
|
|
|
POAG
|
[NCBI]
|
6.48297e-06
|
|
|
FOXP3
|
[NCBI]
|
6.47462e-06
|
|
|
B2M
|
[NCBI]
|
5.85046e-06
|
|
|
IL3
|
[NCBI]
|
5.73656e-06
|
|
|
TSHR
|
[NCBI]
|
5.73656e-06
|
|
|
LSA
|
[NCBI]
|
5.55071e-06
|
|
|
MUC1
|
[NCBI]
|
5.16652e-06
|
|
|
VDR
|
[NCBI]
|
4.85562e-06
|
|
|
MYOC
|
[NCBI]
|
4.58413e-06
|
|
|
IGER
|
[NCBI]
|
4.35879e-06
|
|
|
GTS
|
[NCBI]
|
3.70227e-06
|
|
|
apc gene
|
[NCBI]
|
3.68466e-06
|
|
|
RNASE2
|
[NCBI]
|
3.59167e-06
|
|
|
APS1
|
[NCBI]
|
3.41448e-06
|
|
|
IFNA1
|
[NCBI]
|
3.19168e-06
|
|
|
CEACAM5
|
[NCBI]
|
3.16144e-06
|
|
|
STAT1
|
[NCBI]
|
3.08669e-06
|
|
|
GC
|
[NCBI]
|
2.93615e-06
|
|
|
NGFR
|
[NCBI]
|
2.72475e-06
|
|
|
ADA
|
[NCBI]
|
2.72029e-06
|
|
|
AFP
|
[NCBI]
|
2.49986e-06
|
|
|
KITLG
|
[NCBI]
|
2.46698e-06
|
|
|
CFTR
|
[NCBI]
|
2.1915e-06
|
|
|
RNASE3
|
[NCBI]
|
2.04202e-06
|
|
|
LQT1
|
[NCBI]
|
1.89873e-06
|
|
|
APOE
|
[NCBI]
|
1.63741e-06
|
|
|
TLR4
|
[NCBI]
|
1.62187e-06
|
|
|
EIG
|
[NCBI]
|
1.51838e-06
|
|
|
krabbe disease
|
[NCBI]
|
1.51838e-06
|
|
|
breast cancer
|
[NCBI]
|
1.35945e-06
|
|
|
COMP
|
[NCBI]
|
1.30685e-06
|
|
|
PPARA
|
[NCBI]
|
1.24982e-06
|
|
|
SPP1
|
[NCBI]
|
1.15835e-06
|
|
|
PCD
|
[NCBI]
|
1.11905e-06
|
|
|
CPI
|
[NCBI]
|
9.38288e-07
|
|
|
GAPDH
|
[NCBI]
|
7.38144e-07
|
|
|
EV
|
[NCBI]
|
6.15407e-07
|
|
|
LRP1
|
[NCBI]
|
4.89802e-07
|
|
|
CNTF
|
[NCBI]
|
4.84814e-07
|
|
|
TTR
|
[NCBI]
|
4.6295e-07
|
|
|
ACPP
|
[NCBI]
|
2.097e-07
|
|
|
SCZD
|
[NCBI]
|
8.44615e-08
|
|
|
MAG
|
[NCBI]
|
5.16529e-08
|
|
|
EPO
|
[NCBI]
|
5.16386e-08
|
|
|
GFAP
|
[NCBI]
|
4.8521e-08
|
|
|
SCA1
|
[NCBI]
|
3.9276e-08
|
|
|
SOD2
|
[NCBI]
|
3.79294e-08
|
|
|
IBD1
|
[NCBI]
|
3.16155e-08
|
|
|
PCNA
|
[NCBI]
|
3.13696e-08
|
|
|
asthma, susceptibility to
|
[NCBI]
|
8.75303e-09
|
|
|
JMML
|
[NCBI]
|
4.55646e-09
|
|
|
PF4
|
[NCBI]
|
4.44905e-09
|
|
|
MB
|
[NCBI]
|
3.16105e-09
|
|
|
CTGF
|
[NCBI]
|
1.44271e-09
|
|
|
BCGF
|
[NCBI]
|
1.75432e-10
|
|